clinical trials

Absolute Medical Center LLC is a multidisciplinary outpatient care and clinical research center in Miami, Florida, led by CEO Juan Carlos Diaz. It conducts clinical trials and studies to develop new treatments, medications, and medical devices, following FDA, EMA, and GCP standards, and offers monitoring, data collection, and regulatory compliance services.

clinical researchdata collectionmedical device trialspatient monitoringregulatory compliancestatistical analysis

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to tackling the global nicotine dependence epidemic by advancing cytisinicline as a treatment for smoking and vaping cessation. The company is focused on addressing the global smoking health epidemic through the development and commercialization of cytisinicline, which, if approved, has the potential to become the first new FDA-approved treatment option in 20 years.

commercializationpharmaceutical development

ACM Global Laboratories is a laboratory specializing in clinical trials, central lab services, and toxicology. It delivers state-of-the-art services globally, providing actionable clinical insights on a global scale.

central lab servicestoxicology testing

Actinogen Medical Ltd (ACN 086 778 476) is an ASX-listed (code ACW) clinical-stage company developing Xanamem® (emestedastat), an oral therapeutic that controls levels of the stress hormone cortisol in the brain by inhibiting the 11β-HSD1 enzyme. It is developing Xanamem for Alzheimer's disease, Major Depressive Disorder, and other neurological conditions, and has conducted multiple clinical trials including a Phase 2b/3 Alzheimer's disease trial.

clinical developmentdrug development

Neurology One is a neurology center in Orlando, Florida, dedicated to brain health, early diagnosis, and compassionate care. Its fellowship-trained neurologists specialize in Alzheimer's, Dementia, Parkinson's, and other cognitive, memory, and movement disorders. The practice includes specialized centers for Alzheimer's & Memory Disorders, Parkinson's & Movement Disorders, Neuro Fit brain health and wellness, infusion and IV therapy, and clinical research. The team provides care in English, Spanish, and Mandarin.

BOTOX/XEOMIN/MYOBLOC injectionscare in English, Spanish, and Mandarinclinical researchinfusion and IV therapyneurological evaluation

ADvantage Therapeutics is a clinical-stage biotechnology company developing novel therapeutics to treat neurodegenerative conditions, with a major focus on Alzheimer's Disease. Its lead candidate AD04 is an immuno-stimulant being developed as a disease-modifying therapy for early Alzheimer's Disease. The company was founded in 2021 and has a research team and laboratory at the Vienna BioCenter.

immunotherapy developmentmRNA therapeuticsneuroscience research

Aethlon Medical develops immunotherapeutic technologies to combat cancer and infectious disease. Its Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The FDA has designated the Hemopurifier® as a Breakthrough Device for advanced or metastatic cancer unresponsive or intolerant to standard-of-care therapy and for life-threatening viruses not addressed with approved therapies. The company is conducting a safety, feasibility and dose-finding clinical trial of the Hemop

depletion of exosomes and circulating virusesimmunotherapeutic technology development

Agastiya Biotech is a next-generation oncology company leveraging systems biology, immunotherapy, and quantum biophysics to develop cancer treatments. Its lead molecule, AB001, is a first-in-class, tumor-agnostic, orally available small molecule therapeutic. Following a Phase I trial with 33 patients across advanced metastatic cancers, Phase II trials are underway across multiple cancer types including lung, pancreas, and oral cancers. The company was founded by Dr. Baskaran Pillai and is headquartered in Carlsbad, CA.

Artificial intelligenceimmunotherapymolecular discoveryquantum biophysicssystems biology

Agenus is a clinical-stage immunotherapy company focused on activating the immune system to fight cancer. Its lead program is botensilimab (BOT) plus balstilimab (BAL), a next-generation CTLA-4 plus PD-1 antibody combination designed to convert immune-cold tumors into immune-active ones. The company reports 12 clinical-stage antibody programs and more than 30 years of immunotherapy innovation.

antibody therapeuticsimmunotherapy research and developmentinvestigator-sponsored research

Agios is a biopharmaceutical company founded in 2008 in Cambridge, Massachusetts, focused on cellular metabolism and developing therapies for rare diseases, with a near-term focus on hemolytic and acquired anemias. Its first rare disease therapy was approved by the FDA for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, and it is developing mitapivat and AG-946.

cellular metabolism researchdrug discovery and development

Agitated Solutions, Inc. (ASI) is a Minnesota-based medical device company developing tools to improve ultrasound imaging and aid in diagnosis across multiple clinical applications. Its first product, the Orbis Microbubble Generator, is an ultrasound imaging agent for saline contrast echocardiography studies, licensed in Canada in early 2024. ASI is also developing a novel saline microbubble contrast agent (ASI-02) and a software algorithm to characterize cardiac shunt severity.

medical device developmentultrasound imaging

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. Its lead product, Ampligen (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.

manufacturing & researchResearch and Development

AION Healthspan is a clinical-stage biotechnology company whose mission is to extend human healthspan by developing cellular therapies that prevent, delay, and reverse age-related diseases. Founded on four decades of research at the University of Miami's Diabetes Research Institute and Cell Transplant Center, it is developing its REJUVXL™ cell therapy platform, with a Phase 1/2a clinical trial in Chronic Kidney Disease that commenced in Q1 2025, and plans to expand to indications including acute lung conditions and diabetes.

cell therapy developmentregenerative medicine research

AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. Founded in 2016 by pioneers in the stem cell industry, it uses an autologous personal immunotherapy platform of dendritic cells loaded with tumor cells or multiple pathogen antigens. It also develops proprietary stem cell media and manufacturing methods, and a skin care product line.

autologous cell therapydirected high-purity differentiationstem cell growthvaccine manufacturing

Akagera Medicines is a private Delaware-registered company founded in 2018 in Kigali, Rwanda, that develops novel and patented liposomal formulations of antibacterial drugs to treat tuberculosis and other infectious diseases. It is majority-owned by the people of Rwanda and has laboratories in Boston and San Francisco, plus a 100%-owned subsidiary in Kigali registered in 2022 for future manufacturing and clinical trials.

drug deliveryin vitro testingliposomal formulationmanufacturing (planned)medicinal chemistrypre-clinical studiessmall-molecule drug engineering

Alcanza Clinical Research is a mission-focused investigator site network that conducts clinical trials across a wide range of therapeutic areas, including neurology, psychiatry, general medicine, vaccines, and cardiometabolic diseases. Through its nationwide network of research sites across the United States and Puerto Rico, it connects patients with studies and aims to expand access to clinical research.

clinical researchinvestigator site network

Alexion, AstraZeneca Rare Disease, is a biopharmaceutical company pioneering new possibilities for the rare disease community. Built on a legacy of turning pioneering science into transformative treatments, it develops therapies for rare diseases, with leadership in complement science, and works with patients, advocacy groups and research teams to improve outcomes for people impacted by rare diseases globally.

complement scienceData Science and AIdiagnosticsgenomic medicinerare disease research and development

Alleviant Medical is a medical device company developing next-generation therapies for heart failure. Its Alleviant (ALV1) System is an investigational, minimally invasive interatrial shunt therapy designed to reduce excess pressure in the heart without leaving behind a permanent implant. It is being evaluated in heart failure patients through the FDA-approved ALLAY-HF and ALLAY-HFrEF clinical trial programs.

minimally invasive interatrial shunt procedure

Allied Research Society is a worldwide supplier of disease-state plasma, serum, and controls for the diagnostic and biotech industries. It collects and supplies rare, highly characterized human biological materials for research, studies, and new product development, supporting in-vitro diagnostic (IVD) test kit development. The company holds a CDC permit, is registered with the FDA, and operates with an Internal Review Board (IRB).

biological material collectioncustom sample collectionin-vitro diagnostic (IVD) test kit development support

Alpha Tau Medical is a clinical-stage oncology company pioneering intratumoral alpha-emitting radiotherapeutics to address multiple solid tumor types, including those with few or no currently viable treatment options. Its Alpha DaRT® delivery systems use tiny sources containing radium-224 placed into tumors to release alpha particles that destroy cancer cells from within.

intratumoral alpha-emitting radiotherapypre-clinical research

Alphyn Biologics is a clinical-stage dermatology life science company developing first-in-class Multi-Target Therapeutics (MTT) for severe and prevalent skin diseases based on its Zabalafin Platform (AB-101 Platform). Its lead product candidate, zabalafin hydrogel (AB-101a), is in development for mild-to-moderate atopic dermatitis and has completed a Phase 2a clinical trial. The company became operational in March 2020 and is based in Annapolis, Maryland and Cincinnati, Ohio, with an Australian subsidiary and a European presence in Vienna, Austria.

drug developmentQuality Systems ManagementRegulatory Affairs

ImmunityBio is a biotechnology company founded in 2014 that develops immunotherapies and cell therapies designed to activate both innate and adaptive immune responses to treat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept), is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer. The company also develops a natural killer cell platform and potential cancer vaccines.

cell therapyimmunotherapy developmentnatural killer cell platformresearch and manufacturing

Transform Therapies, Reimagine Lives Our Mission Transform treatment for immune-mediated diseases, empower people to reimagine their lives. About Alumis Our Programs We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases. PIPELINE Our Approach Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development. science Our Culture We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward. careers News October 9, 2026 Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures September 4, 2026 Alumis to Participate in Upcoming.

data analytics platformdrug discoverytherapeutic development

Amgen is a biotechnology company that discovers, develops, manufactures and delivers innovative medicines for serious illnesses. Founded in 1980 in Thousand Oaks, California, it pioneered the use of living cells to make biologic medicines and focuses on general medicine, rare disease, inflammation and oncology, with a presence in approximately 100 countries.

AI and data science in drug discoverybiotechnologydrug discoverymanufacturing of biologic medicinesResearch and Development